CelLBxHealth plc Share Price
Stocks
CLBX
GB0034330679
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
London S.E.
16:35:03 16/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.8000 GBX | -3.03% |
|
-5.88% | -27.27% |
| 10-14 | CelLBxHealth expands services deal with US pharmaceutical firm | AN |
| 10-14 | Cellbxhealth Expands Parsortix Platform Partnership with Pharmaceutical Company in US | MT |
| Market Cap | 9.09M 12.13M 10.78M 9.99M 17.16M 1.15B 17.43M 120M 47.09M 601M 45.52M 44.55M 1.91B | P/E 2026 * |
-0.34x | P/E 2027 * | -8.89x |
|---|---|---|---|---|---|
| Enterprise Value | 7.49M 9.99M 8.88M 8.23M 14.14M 948M 14.36M 98.97M 38.8M 495M 37.51M 36.71M 1.58B | EV / Sales 2026 * |
0.5x | EV / Sales 2027 * | 0.39x |
| Free-Float |
95.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| CLBX | Delayed | |
Deutsche Boerse AG
| DWV | Delayed |
Last Transcript: CelLBxHealth plc
| 16/10/25 | Angle names Peter Collins as interim CEO | AN |
| 28/05/25 | RBC cuts National Grid; Citigroup cuts South32 | AN |
| 23/01/25 | HSBC raises FirstGroup, Goldman cuts Ithaca | AN |
| 14/09/23 | JPMorgan ups Rio Tinto; Redburn likes Carnival | AN |
| 24/01/22 | Berenberg Initiates Angle With Buy Rating, Sets PT | MT |
| 1 day | -3.03% | ||
| 1 week | -5.88% | ||
| Current month | -5.88% | ||
| 1 month | -23.81% | ||
| 3 months | -36.00% | ||
| 6 months | -11.11% | ||
| Current year | -27.27% |
| 1 week | 0.8 |  | 1 |
| 1 month | 0.7 | | 1.1 |
| Current year | 0.7 | | 2.8 |
| 1 year | 0.7 | | 3.5 |
| 3 years | 0.7 | | 37.4 |
| 5 years | 0.7 | | 163.75 |
| 10 years | 0.7 | | 163.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sinéad Armstrong
DFI | Director of Finance/CFO | - | 31/12/1998 |
| Chief Tech/Sci/R&D Officer | - | 31/12/2024 | |
Karen Miller
CTO | Chief Tech/Sci/R&D Officer | - | 04/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Jan Groen
CHM | Chairman | 67 | 21/05/2023 |
Klaas de Boer
BRD | Director/Board Member | 61 | 11/01/2026 |
| Director/Board Member | 61 | 11/01/2026 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/12/25 | Buy | Chief Executive Officer | 5,000,000 | 1.5497% | ||
| 19/12/25 | Buy | Chief Financial Officer | 2,500,000 | 0.7749% | ||
| 19/12/25 | Buy | Chairman | 5,000,000 | 1.5497% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.03% | -5.88% | -54.29% | -93.73% | 12.13M | |
| -0.93% | +4.86% | +28.54% | +41.24% | 255B | |
| -1.06% | +4.20% | +8.59% | +8.83% | 161B | |
| -0.27% | +0.65% | -1.82% | +55.64% | 151B | |
| +0.57% | +3.88% | -54.60% | -11.40% | 64.33B | |
| +1.47% | +5.90% | -12.94% | -13.05% | 51.9B | |
| -1.70% | +1.63% | +19.20% | +21.51% | 49.92B | |
| -0.85% | +4.81% | +6.02% | +46.42% | 50.25B | |
| -1.47% | +1.42% | +22.59% | +55.13% | 48.77B | |
| -1.62% | +0.73% | +30.48% | +71.24% | 42.93B | |
| Average | -0.89% | +2.69% | -0.82% | +18.18% | 87.5B | |
| Weighted average by Cap. | -0.69% | +4.13% | +9.00% | +32.08% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.13M 20.19M 17.95M 16.63M 28.56M 1.92B 29.01M 200M 78.39M 1B 75.77M 74.15M 3.19B | 27.03M 36.06M 32.06M 29.71M 51.01M 3.42B 51.83M 357M 140M 1.79B 135M 132M 5.69B |
| Net income | -8.55M -11.41M -10.14M -9.4M -16.13M -1.08B -16.39M -113M -44.29M -565M -42.81M -41.9M -1.8B | -1.85M -2.47M -2.19M -2.03M -3.49M -234M -3.55M -24.44M -9.58M -122M -9.26M -9.07M -390M |
| Net Debt | -1.6M -2.13M -1.9M -1.76M -3.02M -203M -3.07M -21.14M -8.29M -106M -8.01M -7.84M -337M | 1.4M 1.87M 1.66M 1.54M 2.64M 177M 2.68M 18.5M 7.25M 92.5M 7.01M 6.86M 295M |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/10/26 | GBX 0.8000 | -3.03% | 4,314,280 |
| 15/10/26 | GBX 0.8250 | -2.94% | 2,401,959 |
| 14/10/26 | GBX 0.8500 | -8.11% | 4,412,016 |
| 13/10/26 | GBX 0.9250 | +8.82% | 3,745,113 |
| 12/10/26 | GBX 0.8500 | 0.00% | 889,135 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Annual profits - Rate of surprise
- Stock Market
- Stocks
- CLBX Stock
Select your edition
All financial news and data tailored to specific country editions
